SB 1309: Health care coverage: lung cancer.
- Session Year: 2025-2026
- House: Senate
- Latest Version Date: 2026-06-18
Current Status:
In Progress
(2026-08-13: August 13 hearing: Held in committee and under submission.)
Introduced
In Committee
Awaiting First Chamber Vote
Passed First Chamber
In Committee
Awaiting Second Chamber Vote
Passed Second Chamber
Enacted
Existing law, the Knox-Keene Health Care Service Plan Act of 1975, provides for the licensure and regulation of health care service plans by the Department of Managed Health Care, and makes a willful violation of the act a crime. Existing law provides for the regulation of health insurers by the Department of Insurance. Existing law requires a health care service plan contract or health insurance policy to provide coverage for all generally medically accepted cancer screening tests.
This bill would require a health care service plan contract, except as specified, contract or health insurance policy policy, except as specified, that is issued, amended, or renewed on or after January 1, 2027, to provide coverage for followup screening or diagnostic services for lung cancer, as specified. The bill would prohibit a contract or policy from imposing a copayment, coinsurance, deductible, or any other form of cost sharing for this coverage. If a health care service plan contract or health insurance policy is a high deductible health plan, the bill would prohibit the contract or policy from imposing a deductible, coinsurance, or any other cost sharing on this coverage unless not imposing the deductible, coinsurance, or cost sharing would conflict with the federal requirements for high deductible health plans. Because a willful violation of these provisions by a health care service plan would be a crime, the bill would impose a state-mandated local program.
The California Constitution requires the state to reimburse local agencies and school districts for certain costs mandated by the state. Statutory provisions establish procedures for making that reimbursement.
This bill would provide that no reimbursement is required by this act for a specified reason.
Existing law, the Knox-Keene Health Care Service Plan Act of 1975, provides for the licensure and regulation of health care service plans by the Department of Managed Health Care, and makes a willful violation of the act a crime. Existing law provides for the regulation of health insurers by the Department of Insurance. Existing law requires a health care service plan contract or health insurance policy to provide coverage for all generally medically accepted cancer screening tests.
This bill would require a health care service plan contract contract, except as specified, or health insurance policy issued, amended, or renewed on or after January 1, 2027, to provide coverage for followup screening or diagnostic services for lung cancer, as specified. The bill would prohibit a contract or policy from imposing a copayment, coinsurance, deductible, or any other form of cost sharing for this coverage. If a health care service plan contract is a high deductible health plan, the bill would prohibit the contract from imposing a deductible, coinsurance, or any other cost sharing on this coverage unless not imposing the deductible, coinsurance, or cost sharing would conflict with the federal requirements for high deductible health plans. Because a willful violation of these provisions by a health care service plan would be a crime, the bill would impose a state-mandated local program.
The California Constitution requires the state to reimburse local agencies and school districts for certain costs mandated by the state. Statutory provisions establish procedures for making that reimbursement.
This bill would provide that no reimbursement is required by this act for a specified reason.
Existing law, the Knox-Keene Health Care Service Plan Act of 1975, provides for the licensure and regulation of health care service plans by the Department of Managed Health Care, and makes a willful violation of the act a crime. Existing law provides for the regulation of health insurers by the Department of Insurance. Existing law requires a health care service plan contract or health insurance policy to provide coverage for all generally medically accepted cancer screening tests.
This bill would require a health care service plan contract or health insurance policy issued, amended, or renewed on or after January 1, 2027, that provides coverage for hospital, medical, or surgical expenses to provide coverage for followup screening or diagnostic services for lung cancer, as specified. The bill would prohibit a contract or policy from imposing a copayment, coinsurance, deductible, or any other form of cost sharing for this coverage. Because a willful violation of these provisions by a health care service plan would be a crime, the bill would impose a state-mandated local program.
The California Constitution requires the state to reimburse local agencies and school districts for certain costs mandated by the state. Statutory provisions establish procedures for making that reimbursement.
This bill would provide that no reimbursement is required by this act for a specified reason.
Existing law, the Knox-Keene Health Care Service Plan Act of 1975, provides for the licensure and regulation of health care service plans by the Department of Managed Health Care, and makes a willful violation of the act a crime. Existing law provides for the regulation of health insurers by the Department of Insurance. Existing law requires a health care service plan contract or health insurance policy to provide coverage for all generally medically accepted cancer screening tests.
This bill would require a health care service plan contract or health insurance policy issued, amended, or renewed on or after January 1, 2027, that provides coverage for hospital, medical, or surgical expenses to provide coverage for followup screening or diagnostic services for lung cancer, as specified. The bill would prohibit a contract or policy from imposing a copayment, coinsurance, deductible, or any other form of cost sharing for this coverage. Because a willful violation of these provisions by a health care service plan would be a crime, the bill would impose a state-mandated local program.
The California Constitution requires the state to reimburse local agencies and school districts for certain costs mandated by the state. Statutory provisions establish procedures for making that reimbursement.
This bill would provide that no reimbursement is required by this act for a specified reason.
(a)A health care service plan contract, excluding a specialized health care service plan contract, issued, amended, or renewed on or after January 1, 2027, shall provide coverage for followup screening or diagnostic services for lung cancer recommended by a health care provider acting within the scope of their practice.
(b)(1)Coverage required pursuant to this section shall not be subject to copayment, coinsurance, deductible, or any other form of cost sharing.
(2)Notwithstanding paragraph (1), if a health care service plan contract is a high deductible health plan, as defined in Section 223(c)(2) of Title 26 of the United States Code, the contract shall not impose a deductible, coinsurance, or any other cost sharing on the coverage required pursuant to this section unless not imposing the deductible, coinsurance, or cost sharing would conflict with the federal requirements for high deductible health plans, including those requirements defining exempt preventive care.
(c)For purposes of this section, followup screening or diagnostic services for lung cancer means a service provided after an initial abnormal or indeterminate test result, including, but not limited to, a diagnostic computed tomography scan, positron emission tomography/computed tomography scan, tissue sampling, biopsy, bronchoscopy, pathology, and surgical consultation.
SEC. 2.Section 10123.78 is added to the Insurance Code, to read:10123.78.(a)A health insurance policy issued, amended, or renewed on or after January 1, 2027, shall provide coverage for followup screening or diagnostic services for lung cancer recommended by a health care provider acting within the scope of their practice.
(b)(1)Coverage required pursuant to this section shall not be subject to copayment, coinsurance, deductible, or any other form of cost sharing.
(2)Notwithstanding paragraph (1), if a health insurance policy is a high deductible health plan, as defined in Section 223(c)(2) of Title 26 of the United States Code, the policy shall not impose a deductible, coinsurance, or any other cost sharing on the coverage required pursuant to this section unless not imposing the deductible, coinsurance, or cost sharing would conflict with the federal requirements for high deductible health plans, including those requirements defining exempt preventive care.
(c)For purposes of this section, followup screening or diagnostic services for lung cancer means a service provided after an initial abnormal or indeterminate test result, including, but not limited to, a diagnostic computed tomography scan, positron emission tomography/computed tomography scan, tissue sampling, biopsy, bronchoscopy, pathology, and surgical consultation.
(d)This section does not apply to a specialized health insurance policy that covers only dental, mental health, or vision benefits.
SEC. 3.No reimbursement is required by this act pursuant to Section 6 of Article XIIIB of the California Constitution because the only costs that may be incurred by a local agency or school district will be incurred because this act creates a new crime or infraction, eliminates a crime or infraction, or changes the penalty for a crime or infraction, within the meaning of Section 17556 of the Government Code, or changes the definition of a crime within the meaning of Section 6 of Article XIIIB of the California Constitution.
(a)A health care service plan contract contract, excluding a specialized health care service plan contract, issued, amended, or renewed on or after January 1, 2027, shall provide coverage for followup screening or diagnostic services for lung cancer recommended by a health care provider acting within the scope of their practice.
(b)(1)Coverage required pursuant to this section shall not be subject to copayment, coinsurance, deductible, or any other form of cost sharing.
(2)Notwithstanding paragraph (1), if a health care service plan contract is a high deductible health plan, as defined in Section 223(c)(2) of Title 26 of the United States Code, the contract shall not impose a deductible, coinsurance, or any other cost sharing on the coverage required pursuant to this section unless not imposing the deductible, coinsurance, or cost sharing would conflict with the federal requirements for high deductible health plans, including those requirements defining exempt preventive care.
(c)For purposes of this section, followup screening or diagnostic services for lung cancer means a service provided after an initial abnormal or indeterminate test result, including, but not limited to, a diagnostic computed tomography scan, positron emission tomography/computed tomography scan, tissue sampling, biopsy, bronchoscopy, pathology, and surgical consultation.
SEC. 2.Section 10123.78 is added to the Insurance Code, to read:10123.78.(a)A health insurance policy issued, amended, or renewed on or after January 1, 2027, shall provide coverage for followup screening or diagnostic services for lung cancer recommended by a health care provider acting within the scope of their practice.
(b)Coverage required pursuant to this section shall not be subject to copayment, coinsurance, deductible, or any other form of cost sharing.
(c)For purposes of this section, followup screening or diagnostic services for lung cancer means a service provided after an initial abnormal or indeterminate test result, including, but not limited to, a diagnostic computed tomography scan, positron emission tomography/computed tomography scan, tissue sampling, biopsy, bronchoscopy, pathology, and surgical consultation.
SEC. 3.No reimbursement is required by this act pursuant to Section 6 of Article XIIIB of the California Constitution because the only costs that may be incurred by a local agency or school district will be incurred because this act creates a new crime or infraction, eliminates a crime or infraction, or changes the penalty for a crime or infraction, within the meaning of Section 17556 of the Government Code, or changes the definition of a crime within the meaning of Section 6 of Article XIIIB of the California Constitution.
(a)A health care service plan contract issued, amended, or renewed on or after January 1, 2027, that provides coverage for hospital, medical, or surgical expenses shall provide coverage for followup screening or diagnostic services for lung cancer recommended by a health care provider acting within the scope of their practice.
(b)Coverage required pursuant to this section shall not be subject to copayment, coinsurance, deductible, or any other form of cost sharing.
(c)For purposes of this section, followup screening or diagnostic services for lung cancer means a service provided after an initial abnormal or indeterminate test result, including including, but not limited to, a diagnostic computed tomography scan, positron emission tomography/computed tomography scan, tissue sampling, biopsy, bronchoscopy, pathology, and surgical consultation.
SEC. 2.Section 10123.78 is added to the Insurance Code, to read:10123.78.(a)A health insurance policy issued, amended, or renewed on or after January 1, 2027, that provides coverage for hospital, medical, or surgical expenses shall provide coverage for followup screening or diagnostic services for lung cancer recommended by a health care provider acting within the scope of their practice.
(b)Coverage required pursuant to this section shall not be subject to copayment, coinsurance, deductible, or any other form of cost sharing.
(c)For purposes of this section, followup screening or diagnostic services for lung cancer means a service provided after an initial abnormal or indeterminate test result, including including, but not limited to, a diagnostic computed tomography scan, positron emission tomography/computed tomography scan, tissue sampling, biopsy, bronchoscopy, pathology, and surgical consultation.
SEC. 3.No reimbursement is required by this act pursuant to Section 6 of Article XIIIB of the California Constitution because the only costs that may be incurred by a local agency or school district will be incurred because this act creates a new crime or infraction, eliminates a crime or infraction, or changes the penalty for a crime or infraction, within the meaning of Section 17556 of the Government Code, or changes the definition of a crime within the meaning of Section 6 of Article XIIIB of the California Constitution.
(a)A health care service plan contract issued, amended, or renewed on or after January 1, 2027, that provides coverage for hospital, medical, or surgical expenses shall provide coverage for followup screening or diagnostic services for lung cancer recommended by a health care provider acting within the scope of their practice.
(b)Coverage required pursuant to this section shall not be subject to copayment, coinsurance, deductible, or any other form of cost sharing.
(c)For purposes of this section, followup screening or diagnostic services for lung cancer means a service provided after an initial abnormal or indeterminate test result, including a diagnostic computed tomography scan, positron emission tomography/computed tomography scan, tissue sampling, biopsy, bronchoscopy, pathology, and surgical consultation.
SEC. 2.Section 10123.78 is added to the Insurance Code, to read:10123.78.(a)A health insurance policy issued, amended, or renewed on or after January 1, 2027, that provides coverage for hospital, medical, or surgical expenses shall provide coverage for followup screening or diagnostic services for lung cancer recommended by a health care provider acting within the scope of their practice.
(b)Coverage required pursuant to this section shall not be subject to copayment, coinsurance, deductible, or any other form of cost sharing.
(c)For purposes of this section, followup screening or diagnostic services for lung cancer means a service provided after an initial abnormal or indeterminate test result, including a diagnostic computed tomography scan, positron emission tomography/computed tomography scan, tissue sampling, biopsy, bronchoscopy, pathology, and surgical consultation.
SEC. 3.No reimbursement is required by this act pursuant to Section 6 of Article XIIIB of the California Constitution because the only costs that may be incurred by a local agency or school district will be incurred because this act creates a new crime or infraction, eliminates a crime or infraction, or changes the penalty for a crime or infraction, within the meaning of Section 17556 of the Government Code, or changes the definition of a crime within the meaning of Section 6 of Article XIIIB of the California Constitution.
|
Date
|
Status
|
|---|---|
| Aug 13, 2026 | August 13 hearing: Held in committee and under submission. |
| Jul 1, 2026 | July 1 set for first hearing. Placed on suspense file. |
| Jun 18, 2026 | Read second time and amended. Re-referred to Com. on APPR. |
| Jun 17, 2026 | From committee: Do pass as amended and re-refer to Com. on APPR. (Ayes 15. Noes 0.) (June 16). |
| May 26, 2026 | Referred to Com. on HEALTH. |
| May 20, 2026 | In Assembly. Read first time. Held at Desk. |
| May 19, 2026 | Read third time. Passed. (Ayes 38. Noes 0. Page 4349.) Ordered to the Assembly. |
| May 19, 2026 | Read third time. Passed. (Ayes 38. Noes 0.) Ordered to the Assembly. |
| May 14, 2026 | From committee: Do pass. (Ayes 7. Noes 0. Page 4272.) (May 14). |
| May 14, 2026 | Read second time. Ordered to third reading. |
| May 14, 2026 | From committee: Do pass. (Ayes 7. Noes 0.) (May 14). |
| May 8, 2026 | Set for hearing May 14. |
| May 4, 2026 | May 4 hearing: Placed on APPR. suspense file. |
| Apr 28, 2026 | Set for hearing May 4. |
| Apr 27, 2026 | Read second time and amended. Re-referred to Com. on APPR. |
| Apr 23, 2026 | From committee: Do pass as amended and re-refer to Com. on APPR. (Ayes 10. Noes 0. Page 4011.) (April 22). |
| Apr 23, 2026 | From committee: Do pass as amended and re-refer to Com. on APPR. (Ayes 10. Noes 0.) (April 22). |
| Apr 14, 2026 | From committee with author's amendments. Read second time and amended. Re-referred to Com. on HEALTH. |
| Apr 13, 2026 | Set for hearing April 22. |
| Mar 4, 2026 | Referred to Com. on HEALTH. |
| Feb 23, 2026 | Read first time. |
| Feb 23, 2026 | From printer. May be acted upon on or after March 23. |
| Feb 20, 2026 | Introduced. To Com. on RLS. for assignment. To print. |
|
Date
|
Description
|
Location
|
Votes
|
|
|---|---|---|---|---|
| Jun 16, 2026 | Do pass as amended and be re-referred to the Committee on [Appropriations] | Assembly Standing Committee on Health |
Passed |
|
| May 19, 2026 | Senate 3rd Reading SB1309 Rubio | Senate Floor |
Passed |
|
| May 14, 2026 | Do pass | Senate Standing Committee on Appropriations |
Passed |
|
| May 4, 2026 | Placed on suspense file | Senate Standing Committee on Appropriations |
Passed |
|
| Apr 22, 2026 | Do pass as amended, but first amend, and re-refer to the Committee on [Appropriations] | Senate Standing Committee on Health |
Passed |
This list shows positions taken on this bill by organizations on the date displayed, which is linked to the original source.
Positions by individuals are not included.
|
Organization
|
Position
|
Date
|
|---|---|---|
| Alliance for Patient Access | ** Support | |
| American Cancer Society Cancer Action Network | ** Support | |
| American Lung Association | ** Support | |
| American Lung Cancer Screening Initiative | ** Support | |
| Association Of California Life And Health Insurance Companies | ** Against | |
| Astrazeneca | ** Support | |
| Biocom | ** Support | |
| Biomarker Collaborative | ** Support | |
| Breathe California of the Bay Area, Golden Gate andCentral Coast | ** Support | |
| Breathe California Sacramento Region | ** Support | |
| Breathe Southern California | ** Support | |
| California Academy Of Family Physicians | ** Support | |
| California Association Of Health Plans | ** Against | |
| California Black Health Network | ** Support | |
| California Chronic Care Coalition | ** Support | |
| California Life Sciences | ** Support | |
| California Medical Association | ** Support | |
| California Professional Firefighters | ** Support | |
| California Small Business Association | ** Against | |
| California Society For Respiratory Care | ** Support | |
| Cedars-Sinai Health Systems | ** Support | |
| Go2 for Lung Cancer | ** Support | |
| Health Access California | ** Support | |
| ICAN, International Cancer Advocacy Network | ** Support | |
| International Cancer Advocacy Network | ** Support |
Date of Hearing: July 1, 2026
ASSEMBLY COMMITTEE ON APPROPRIATIONS
Buffy Wicks, Chair
SBPCA Bill Id:SB 1309
Author:(Rubio) – As Amended Ver:June 18, 2026
Policy Committee: | Health | Vote: | 15 - 0 |
|
| ||
|
|
Urgency: No State Mandated Local Program: Yes Reimbursable: No
SUMMARY:
This bill requires health plans and health insurance policies provide coverage without cost sharing for follow-up screenings and diagnostic services for lung cancer after an abnormal or indeterminate screening result.
Specifically, this bill:
- Requires health care service plans and health insurers (collectively, health plans), except specialized health plans, to provide coverage for follow-up screening or diagnostic services for lung cancer recommended by a health care provider acting within their scope of practice.
- Prohibits coverage in item 1, above, from being subject to copayment, coinsurance, deductible, or any other form of cost sharing.
- For a high deductible health plan, prohibits the imposition of a deductible, coinsurance, or any other cost sharing on the coverage required pursuant to this bill unless not imposing the deductible, coinsurance, or cost sharing would conflict with the federal requirements for high deductible health plans, including those requirements defining exempt preventive care.
- Defines “follow-up screening or diagnostic services for lung cancer” as a service provided after an initial abnormal or indeterminate test result, including, but not limited to, a diagnostic computed tomography scan, positron emission tomography/computed tomography scan, tissue sampling, biopsy, bronchoscopy, pathology, and surgical consultation.
FISCAL EFFECT:
- The California Health Benefits Review Program (CHBRP) estimates premium costs to the California Public Employees Retirement System (CalPERS): CHBRP estimates that premium costs for CalPERS would increase by $544,000, of which approximately $250,000 would be General Fund (GF) costs for premiums for health plans regulated by the Department of Managed Health Care (DMHC). The state would incur additional costs of an unknown amount, likely less than $250,000 GF, for CalPERS insurance policies regulated by the California Department of Insurance (CDI).
- DMHC and CDI estimate minor and absorbable costs.
- CHBRP estimates this bill will increase total premiums for all employers and enrollees by approximately $27.6 million (0.016%) statewide, while decreasing cost sharing by $20.7 million statewide for those enrollees who use the newly mandated benefits. Although most of these costs are not borne by the state, premium increases inflate overall health care costs for employers and enrollees, especially those in the small group and individual insurance markets.
COMMENTS:
- Purpose. This bill is sponsored by the American Cancer Society Cancer Action Network and American Lung Association. According to the author:
Lung cancer is the leading cause of cancer-related death in California, yet it is one of the most survivable cancers when caught early. The problem is that too many Californians are skipping life-saving screenings. Not because they don't want to take care of their health, but because they simply cannot afford to be screened…When a screening returns an abnormal or intermediate result, patients need timely follow-up care to determine next steps, yet this is often where the financial burden becomes overwhelming. [This bill] eliminates cost-sharing for that follow-up care, ensuring patients are not left without answers at the most critical moment in their health journey. The data is clear: when lung cancer is caught at an early stage, survival rates increase dramatically.
- Background. Lung Cancer. Lung cancer is the leading cause of cancer death in the U.S. The top three causes of lung cancer are tobacco smoking, radon gas exposure, and secondhand smoke. While 80% to 90% of lung cancer is caused by inhaled tobacco smoke, 10% to 20% of lung cancer patients have no smoking history. Lung cancer symptoms usually do not appear until later stages, when the cancer has spread and the chance of cure or long-term survival is reduced. In 2024, approximately 16,803 new cases were diagnosed in the state. CHBRP notes that California has among the lowest lung cancer incidence rates in the nation, at 36.5 per 100,000 people, versus the national rate of 52.8 per 100,000. However, a smaller proportion (25.9%) of lung cancer cases are diagnosed at an early stage in California compared to the national average (28.1%). CHBRP states uptake of screening of lung cancer – which is often the initial step for lung cancer diagnosis – is low in California, with only 16.8% of the eligible population getting screened.
Initial and Follow-up Screening. The U.S. Preventive Services Taskforce (USPSTF) recommends people between 50 and 80 years who have a history of smoking get screened annually with a low-dose computed tomography (LDCT) scan. CHBRP defines initial (or baseline) screening as the first LDCT scan performed for lung cancer screening in an eligible, asymptomatic individual. This initial LDCT scan establishes a reference point for future comparisons. CHBRP defines follow-up screening as subsequent LDCT scans performed after the initial screening to monitor findings or continue routine annual screening in accordance with clinical guidelines.
This bill aims to expand access to follow-up screenings for lung cancer by eliminating cost-sharing for those screenings. Initial lung cancer screenings are already covered without cost-sharing for consumers; yet, as noted above, uptake of these initial screenings in California is low.
- Opposition. The California Association of Health Plans (CAPH) and Association of California Life and Health Insurance Companies (ACLHIC) oppose this bill, arguing that this bill does not address the primary barriers to screening uptake and risks increasing costs without meaningfully improving outcomes. CAPH and ACLHIC suggest that cost may not be the primary barrier to screening uptake, that the barriers to lung cancer screening are more likely to occur earlier in the care continuum, rather than at the stage of follow-up diagnostic services, and that improving early detection may depend more on increasing awareness, clarifying eligibility, and strengthening provider engagement than on eliminating cost-sharing for follow-up diagnostic services.
Analysis Prepared by: Allegra Kim / APPR. / (916) 319-2081
Date of Hearing: June 16, 2026
ASSEMBLY COMMITTEE ON HEALTH
Mia Bonta, Chair
SBPCA Bill Id:SB 1309
Author:(Rubio) – As Amended Ver:April 27, 2026
SENATE VOTE: 38-0
SUBJECT: Health care coverage: lung cancer.
SUMMARY: Requires health plans and health insurers to provide coverage for follow-up screening or diagnostic services for lung cancer without cost-sharing. Specifically, this bill:
- Requires a health plan and health insurer to provide coverage for follow-up screening or diagnostic services for lung cancer recommended by a health care provider acting within their scope of practice.
- Prohibits coverage in 1) above from being subject to copayment, coinsurance, deductible, or any other form of cost-sharing.
- Prohibits, if the health plan is a high deductible health plan, the imposition of a deductible, coinsurance, or any other cost-sharing on the coverage required pursuant to this bill unless not imposing the deductible, coinsurance, or cost-sharing would conflict with the federal requirements for high deductible health plans, including those requirements defining exempt preventive care.
- Exempts specialized health plans from the provisions of this bill.
- Defines “follow-up screening or diagnostic services for lung cancer” as a service provided after an initial abnormal or indeterminate test result, including, but not limited to, a diagnostic computed tomography scan, positron emission tomography/computed tomography scan, tissue sampling, biopsy, bronchoscopy, pathology, and surgical consultation.
EXISTING LAW:
- Establishes the Department of Managed Health Care (DMHC) to regulate health plans under the Knox-Keene Health Care Service Plan Act of 1975 (Knox-Keene Act) and the California Department of Insurance (CDI) to regulate health and other insurance. [Health & Safety Code (HSC) § 1340, et seq. and Insurance Code (INS) § 106, et seq.]
- Establishes California's essential health benefits (EHBs) benchmark under the Patient Protection and Affordable Care Act (ACA) as the Kaiser Small Group Health Maintenance Organization, establishes existing California health insurance mandates, and the 10 ACA mandated benefits, including prescription drug coverage. [HSC § 1367.005 and INS § 10112.27]
- Requires a health plan contract and health insurance policy, except for a specialized health plan contract and policy, to be deemed to provide coverage for all generally medically accepted cancer screening tests, subject to all terms and conditions that would otherwise apply. [HSC § 1367.665 and INS § 10123.20]
- Requires health plans and insurers, at a minimum, to provide coverage for and prohibits any cost-sharing requirements for the following:
- Evidence-based items or services that had in effect on January 1, 2025 a rating of “A” or “B” in the recommendations of the United States Preventive Services Taskforce (USPSTF);
- Immunizations that had a recommendation in effect on January 1, 2025 from the Advisory Committee on Immunization Practices (ACIP) of the Center for Disease Control; and,
- With respect to infants, children, adolescents, and women, additional preventive care and screenings provided for in comprehensive guidelines supported by the United States Health Resources and Services Administration (HRSA) as of January 1, 2025. [HSC § 1367.002 and INS § 10112.2]
- Permits the State Department of Public Health (DPH) to modify or supplement baseline recommendations by the USPSTF, ACIP, and HRSA that were in effect on January 1, 2025. Allows DPH to take into consideration guidance and recommendations from additional medical and scientific organizations, including the American Academy of Pediatrics, American College of Obstetricians and Gynecologists, and the American Academy of Family Physicians. [HSC § 120164]
- Establishes the California Health Care Quality and Affordability Act, which creates the Office of Health Care Affordability (OHCA) within the Department of Health Care Access and Information (HCAI). Identifies OHCA’s three primary responsibilities: managing spending targets, monitoring system performance, and assessing market consolidation. Requires OHCA to collect, analyze, and publicly report data on total health care expenditures, and enforce spending targets set by a Health Care Affordability Board. [HSC § 127500, et seq.]
FISCAL EFFECT: According to the Senate Appropriations Committee, DMHC anticipates minor and absorbable costs for state administration, CDI estimates costs of $3,000 in 2026-27 and $16,000 in 2027-28 for state administration (Insurance Fund). Unknown General Fund costs, potentially hundreds of thousands, due to increased California Public Employees' Retirement System (CalPERS) plan premiums.
COMMENTS:
- PURPOSE OF THIS BILL. According to the author, lung cancer is the leading cause of cancer-related death in California, yet it is one of the most survivable cancers when caught early. The problem is that too many Californians are skipping life-saving screenings. Not because they don't want to take care of their health, but because they simply cannot afford to be screened. SB 1309, the Stop Lung Cancer Early Act, directly addresses this barrier by eliminating cost-sharing for lung cancer screenings. There is no reason to delay the care that could save your life. When a screening returns an abnormal or intermediate result, patients need timely follow-up care to determine next steps, yet this is often where the financial burden becomes overwhelming. SB 1309 also eliminates cost-sharing for that follow-up care, ensuring patients are not left without answers at the most critical moment in their health journey. The data is clear: when lung cancer is caught at an early stage, survival rates increase dramatically. By removing financial obstacles at every step of the screening and diagnostic process, this bill will encourage more Californians to get screened, more cancers to be caught early, and ultimately, more lives to be saved. The author states she is proud to author this bill and urges her colleagues to support this commonsense measure. No Californian should have to choose between their financial stability and a fighting chance against cancer.
- BACKGROUND. Lung cancer is the uncontrolled growth of abnormal cells in the lungs, often caused by inhaled toxins. Symptoms usually do not appear until later stages when the cancer has spread and the chance of cure or long-term survival is reduced, which makes early detection critical. The top three causes of lung cancer are tobacco smoking, radon gas exposure, and secondhand smoke. Eighty percent to 90% of lung cancer is caused by inhaled tobacco smoke, but between 10% to 20% of lung cancer patients have no smoking history. California has among the lowest lung cancer incidence rates in the United States, at approximately 36.5 per 100,000 people, well below the national rate of 52.8 per 100,000 people. This may be partially attributed to low overall smoking rates in California compared to other states as well as aggressive anti-tobacco policies. In 2024, approximately 16,803 new cases were diagnosed in the state. Yet, concerns persist that a relatively high share of cases are diagnosed at a later stage, which are associated with lower survival rates.
- California Health Benefits Review Program (CHBRP). CHBRP was created in response to AB 1996 (Thomson), Chapter 795, Statutes of 2002, which requests the University of California to assess legislation proposing a mandated benefit or service and prepare a written analysis with relevant data on the medical, economic, and public health impacts of proposed health plan and health insurance benefit mandate legislation. SB 125 (Hernandez), Chapter 9, Statutes of 2015, added an impact assessment on EHBs, and legislation that impacts health insurance benefit designs, cost-sharing, premiums, and other health insurance topics to CHBRP’s purview. CHBRP reviewed this bill and included the following impact estimates in their analysis:
- Increased premiums, reduced out-of-pocket expenses. CHBRP estimates that SB 1309 would result in an additional 1,000 patients accessing follow-up screenings or services for lung cancer, including imaging, biopsies, and surgical or other specialist consults. A total of 51,000 Californians would utilize these follow-up services without cost-sharing. CHBRP estimates that these utilization changes would lead to an increase of $27,641,000 in total annual premiums paid by employers and enrollees for covering benefits without cost-sharing. Average annual out-of-pocket expenses would decrease for those accessing follow-up screenings and services in the commercial and CalPERS market, ranging from $90 (CalPERS) to $840 (individually purchased insurance).
- Medical effectiveness. CHBRP found that there is strong evidence that delays in diagnosis and treatment are correlated with worse clinical stage during the diagnostic workup and increased recurrence of lung cancer. There is some evidence that treatment delays for lung cancer negatively impact mortality. CHBRP notes that individuals with an abnormal initial screening test result often incur out-of-pocket costs for the follow-up services and screenings that occur after the initial screening, and these out-of-pocket costs have increased over time. CHBRP found no direct evidence on the impact of cost-sharing for follow-up services after an abnormal/indeterminate results for lung cancer. While not specific to lung cancer, there is evidence from studies on breast cancer that shows increased cost-sharing generally contributes to lower utilization of services.
- Public health & long-term impacts. Due to the small changes in utilization or delays in utilization, CHBRP projects a modest public health impact. CHBRP estimates that an unknown number of enrollees would receive an earlier-stage diagnosis than they would have at baseline, with an average cost savings of $149,304 per case.
- California lags in lung cancer screening. CHBRP’s analysis notes that a smaller proportion of lung cancer cases are diagnosed at an early stage in California (25.9%) compared to the national average (28.1%). Uptake of screening of lung cancer – which is often the initial step for lung cancer diagnosis – remains low compared to other cancer screenings. California ranks 32 out of 51 in the nation for lung cancer screening, with only 16.8% of the eligible population getting screened. Lung cancer screening is relatively recent compared to other cancer screening modalities and remains underutilized among eligible populations. Barriers to screening include limited access to care, lack of awareness of screening options, stigma and implicit bias related to smoking and race, perceptions of lung cancer as a fatal condition, challenges with shared decision-making, and underestimation of individual risk. Racial and ethnic disparities in initial lung cancer screening in California show significant gaps in screening eligibility and uptake. Despite 2021 USPSTF guideline expansions, Black, Latino, and Asian American populations in California often have lower screening uptake than white counterparts. Notably, Latino (37.3%), African American (38.4%), and Japanese American (40.0%) patients show the lowest screening eligibility, while Native Hawaiian (56.7%) and white (49.6%) cases show the highest.
- California Health Benefits Review Program (CHBRP). CHBRP was created in response to AB 1996 (Thomson), Chapter 795, Statutes of 2002, which requests the University of California to assess legislation proposing a mandated benefit or service and prepare a written analysis with relevant data on the medical, economic, and public health impacts of proposed health plan and health insurance benefit mandate legislation. SB 125 (Hernandez), Chapter 9, Statutes of 2015, added an impact assessment on EHBs, and legislation that impacts health insurance benefit designs, cost-sharing, premiums, and other health insurance topics to CHBRP’s purview. CHBRP reviewed this bill and included the following impact estimates in their analysis:
This bill aims to expand access to follow-up screenings for lung cancer by eliminating cost-sharing for those screenings. Initial lung cancer screenings are already covered without cost-sharing for consumers, yet evidence shows that uptake of these screenings in California is still incredibly low. This raises the question whether removing cost-sharing for follow-up screenings will increase early detection, or if there are alternative solutions to pursue to increase lung cancer screening rates across California.
- OHCA cost targets. OHCA was established in 2022 in response to widespread cost-related access challenges across California. According to the California Health Care Foundation (CHCF), over half of Californians say they skip or delay health care due to costs. OHCA collects, analyzes, and publicly reports data on total health care expenditures and enforces spending targets. OHCA’s spending targets are intended to reduce excess spending and slow health care spending growth. In April of 2024, OHCA approved a statewide cost growth target of 3.5% starting in 2025 and phasing down to 3% by 2029. Health care entities, including health plans and insurers, are subject to the statewide spending target and are subject to progressive enforcement if the entity’s costs exceed the target. Some entities have raised concerns that new legislative insurance mandates will make it difficult for them to meet the established cost growth target.
Current law does not explicitly require OHCA to adjust the cost growth targets based on changes to state policy, such as insurance mandates, that may increase spending. However, it does require OHCA to consider state benefit mandates in its development and enforcement of cost growth targets. Specifically, when establishing cost growth target methodology, OHCA is required to review relevant state policy changes impacting covered benefits, provider reimbursement, and costs, among other factors. In addition, in enforcing cost growth targets, OHCA is required to consider factors that contribute to spending in excess of the applicable target, and the extent to which each entity has control over the applicable components of its cost target.
- SUPPORT. A coalition of patient, provider, and stakeholder advocates support this bill, including the American Lung Association and American Cancer Society Cancer Action Network. The supporters note that when detected early, lung cancer has a five-year survival rate of approximately 65%, compared to roughly 10% when diagnosed at a later stage. The supporters argue that this bill builds on California’s commitment to preventive care by ensuring that the full screening-to-diagnosis pathway is accessible and effective. The supporters continue that low-dose computed tomography lung cancer screening is generally provided without cost-sharing in California’s individual and group insurance markets, including Medi-Cal managed care, many patients nonetheless face substantial out-of-pocket costs in certain situations for medically necessary follow-up diagnostic procedures after an abnormal screening result. The supporters state that these costs—often in the form of copayments, coinsurance, or deductibles—can range from hundreds to thousands of dollars. The supporters argue that financial barriers frequently discourage or delay patients from completing essential follow-up testing, undermining the life-saving potential of lung cancer screening. The supporters continue that these burdens disproportionately affect low-income Californians, communities of color, and rural populations—groups that already experience higher lung cancer mortality rates. The supporters argue that this bill addresses this critical gap by eliminating cost-sharing for follow-up diagnostic procedures that are clinically indicated after a lung cancer screening. The supporters conclude that by removing financial barriers to timely diagnostic care, this bill will help ensure that more patients complete recommended testing, promote earlier diagnosis, reduce disparities in access to care, improve survival outcomes, and may reduce long-term system costs by avoiding late-state treatment and preventable emergency care.
- OPPOSITION. The California Association of Health Plans and Association of California Life and Health Insurance Companies oppose this bill. The opposition states that they share the author's goal of improving early detection of lung cancer but argue that this bill does not address the primary barriers to screening uptake and risks increasing costs without meaningfully improving outcomes. The opposition cites that initial lung cancer screening rates in California remain low, at approximately 16.8%, despite these screenings already being covered without cost-sharing. The opposition notes this is significantly lower than screening rates for other cancers, and share the example that breast cancer screening rates are closer to 65%. The opposition suggests that cost may not be the primary barrier to screening uptake. The opposition additionally cites research that indicates that the barriers to lung cancer screening are more likely to occur earlier in the care continuum, rather than at the follow-up diagnostic services. These include: provider challenges, such as evolving eligibility criteria and difficulty identifying eligible patients; low patient awareness, including limited understanding of screening availability and benefits; stigma associated with smoking history; and geographic and demographic access disparities. The opposition argues that taken together, these factors suggest that improving early detection may depend more on increasing awareness, clarifying eligibility, and strengthening provider engagement than on eliminating cost-sharing for follow-up diagnostic services. The opposition continues that this bill focuses on eliminating cost-sharing for downstream follow-up services — a later point in the care continuum — while evidence indicates that initial lung cancer screening rates remain far below where they need to be. The opposition concludes that this bill risks increasing costs without meaningfully improving those rates or early detection outcomes.
- RELATED LEGISLATION.
- AB 1570 (Wilson) would have required health plans and insurers to cover an annual cervical cancer screening home test kit without cost-sharing. AB 1570 was held on the Assembly Appropriations suspense file.
- AB 1906 (Aguiar-Curry) would require health plans, health insurance, and Medi-Cal to cover screening mammography and medically necessary diagnostic breast imaging, including imaging following an abnormal mammography for an enrollee or insured with a breast cancer risk factor without cost-sharing. AB 1906 is currently pending in the Senate Health Committee.
- SB 950 (Weber Pierson) would require health plans and insurers to cover all medically necessary treatments or medications, as determined by a health care provider, that are approved by the federal Food and Drug Administration for the treatment of Alzheimer’s disease or other related dementia. SB 950 is currently pending in the Assembly Health Committee.
- SB 1124 (Archuleta) would require DPH to develop signage for lung cancer screening by July 1, 2027, and mandates that retailers prominently display this signage in retail locations beginning January 1, 2028. Would create a $1,000 penalty for failure to display the signage, enforceable by the California Department of Tax and Fee Administration. SB 1124 is currently pending in the Assembly Health Committee.
- TECHNICAL AMENDMENTS. CDI has requested and the author has agreed to amendments to apply exemptions for specialized health care service plans and high deductible health plans in the HSC sections of this bill to the INS code sections, as follows:
INS 10123.78. (a) A health insurance policy issued, amended, or renewed on or after January 1, 2027, shall provide coverage for follow-up screening or diagnostic services for lung cancer recommended by a health care provider acting within the scope of their practice.
(b) (1) Coverage required pursuant to this section shall not be subject to copayment, coinsurance, deductible, or any other form of cost-sharing.
(2) Notwithstanding paragraph (1), if a health insurance policy is a high deductible health plan, as defined in Section 223(c)(2) of Title 26 of the United States Code, the policy shall not impose a deductible, coinsurance, or any other cost-sharing on the coverage required pursuant to this section unless not imposing the deductible, coinsurance, or cost-sharing would conflict with the federal requirements for high deductible health plans, including those requirements defining exempt preventive care.
(c) For purposes of this section, “follow-up screening or diagnostic services for lung cancer” means a service provided after an initial abnormal or indeterminate test result, including, but not limited to, a diagnostic computed tomography scan, positron emission tomography/computed tomography scan, tissue sampling, biopsy, bronchoscopy, pathology, and surgical consultation.
(d) This section does not apply to a specialized health insurance policy that covers only dental, mental health, or vision benefits.
REGISTERED SUPPORT / OPPOSITION:
Support
American Cancer Society Cancer Action Network (sponsor)
American Lung Association (sponsor)
Alliance for Patient Access
AstraZeneca
Biocom
Breathe California of the Bay Area, Golden Gate and Central Coast
Breathe California Sacramento Region
Breathe Southern California
California Academy of Family Physicians
California Black Health Network
California Chronic Care Coalition
California Life Sciences
California Medical Association (CMA)
California Professional Firefighters
California Society for Respiratory Care
Go2 for Lung Cancer
Health Access California
ICAN, International Cancer Advocacy Network
Opposition
Association of California Life & Health Insurance Companies
California Association of Health Plans
Analysis Prepared by: Riana King / HEALTH / (916) 319-2097
SENATE RULES COMMITTEE Office of Senate Floor Analyses (916) 651-4171 | SB 1309 |
THIRD READING
Bill No: SB 1309
Author: Rubio (D)
Amended: 4/27/26
Vote: 21
SENATE HEALTH COMMITTEE: 10-0, 4/22/26
AYES: Weber Pierson, Valladares, Caballero, Durazo, Gonzalez, Menjivar, Padilla, Pérez, Rubio, Smallwood-Cuevas
NO VOTE RECORDED: Grove
SENATE APPROPRIATIONS COMMITTEE: 7-0, 5/14/26
AYES: Cervantes, Seyarto, Cabaldon, Dahle, Grayson, Richardson, Wahab
SUBJECT: Health care coverage: lung cancer
SOURCE: American Cancer Society Cancer Action Network
American Lung Association
DIGEST:
This bill requires a health plan contract or health insurance policy to provide, without cost-sharing, coverage for follow-up screening or diagnostic services for lung cancer that is recommended by a health care provider acting within the scope of their practice.
ANALYSIS:
Existing law:
- Establishes the Department of Managed Health Care (DMHC) to regulate health plans under the Knox-Keene Health Care Service Plan Act of 1975 (Knox-Keene Act); California Department of Insurance (CDI) to regulate health and other insurance; and, the Department of Health Care Services (DHCS) to administer the Medi-Cal program. [Health and Safety Code (HSC) §1340, et seq., Insurance Code (INS) §106, et seq., and Welfare and Institutions Code (WIC) §14000, et seq.]
- Requires a health plan contract and health insurance policy, except for a specialized health plan contract and policy, to be deemed to provide coverage for all generally medically accepted cancer screening tests, subject to all terms and conditions that would otherwise apply. [HSC §1367.665 and INS §10123.20]
- Requires a group or individual nongrandfathered health plan contract or health insurance policy, at a minimum, to provide coverage for and not impose any cost-sharing requirements for any of the following:
- Evidence-based items or services that had in effect a rating of “A” or “B” in the recommendations of the United States Preventive Services Task Force (USPSTF) on January 1, 2025 or, as later modified by the California Department of Public Health (CDPH);
- Immunizations that had in effect a recommendation from the Advisory Committee on Immunization Practices of the federal Centers for Disease Control and Prevention (CDC) on January 1, 2025 or as later modified by CDPH;
- With respect to infants, children, and adolescents, evidence-informed preventive care and screenings provided in the comprehensive guidelines supported by the United States Health Resources and Services Administration (HRSA) as of January 1, 2025 or as later modified by CDPH;
- With respect to women, those additional preventive care and screenings as provided for in comprehensive guidelines supported by the HRSA as of January 1, 2025 or as later modified by CDPH; and,
- Indicates the recommendations of the USPSTF regarding breast cancer screening, mammography, and prevention as of January 1, 2025, or as later modified by CDPH, is considered the most current other than those issued in or around November 2009. [HSC§ 1367.002 and INS §10112.2]
- Establishes health savings accounts under federal law, to be used exclusively for the purpose of paying the qualified medical expenses of the account beneficiary, but only if the written governing instrument creating the trust meets specified requirements. Establishes high deductible health plans, which are plans with deductibles not less than $1,000 for an individual and $5,000 for a family, as specified. [Title 26 United States Code (USC) §223]
- Allows an annual tax deduction in an amount equal to the aggregate amount paid in cash by or on behalf of an individual, to a health savings account. [26 USC §223]
- Prohibits a plan from failing to be treated as a high deductible health plan by reason of failing to have a deductible for preventive care, as specified. [26 USC §223]
This bill:
- Requires a health plan contract or health insurance policy issued, amended, or renewed on or after January 1, 2027 to provide coverage for follow-up screening or diagnostic services for lung cancer recommended by a health care provider acting within the scope of their practice.
- Specifies that this coverage is not subject to copayment, coinsurance, deductible or any other form of cost-sharing.
- Defines “follow-up screening or diagnostic services for lung cancer” as a service provided after an initial abnormal or indeterminate test result, including, but not limited to a diagnostic computed tomography scan, positron emission tomography/computed tomography scan, tissue sampling, biopsy, bronchoscopy, pathology, and surgical consultation.
- Specifies that specialized health care service plan contracts are excluded, as are federally regulated high deductible health plans unless the federal requirements for those plans authorize the provision of these services without a deductible, coinsurance, or any other cost sharing.
Comments
According to the author of this bill:
Lung cancer is the leading cause of cancer-related death in California, yet it is one of the most survivable cancers when caught early. The problem is that too many Californians are skipping life-saving screenings. Not because they do not want to take care of their health, but because they simply cannot afford to be screened. This bill, the Stop Lung Cancer Early Act, directly addresses this barrier by eliminating cost-sharing for lung cancer screenings. There is no reason to delay the care that could save your life. When a screening returns an abnormal or intermediate result, patients need timely follow-up care to determine next steps, yet this is often where the financial burden becomes overwhelming. This bill eliminates cost-sharing for that follow-up care, ensuring patients are not left without answers at the most critical moment in their health journey. The data is clear: when lung cancer is caught at an early stage, survival rates increase dramatically. By removing financial obstacles at every step of the screening and diagnostic process, this bill will encourage more Californians to get screened, more cancers to be caught early, and ultimately, more lives to be saved. No Californian should have to choose between their financial stability and a fighting chance against cancer.
While the argument that the high cost of follow-up care deters people from getting the additional diagnostic tests they need after an abnormal or inconclusive initial lung cancer screening test is compelling, the same argument can be made for the cost of lung cancer treatment itself, or indeed, any health care service. Earlier diagnosis and care is always better and cost always deters access to services. California’s high rate of persons who receive no treatment after being diagnosed with lung cancer is testament to this fact.
Background
Lung Cancer in California. Lung cancer is the third most common cancer and the leading cause of cancer deaths in California, according to data from a 2019 UC Davis Comprehensive Cancer Center report. Smoking and secondhand smoke are the leading risk factors, followed by radon exposure and air pollution. The California Tobacco Control Program’s estimate of lung and bronchus cancer incidence in California decreased from 41.2 to 33.8 per 100,000 adults between 2016 and 2021, although the COVID-19 pandemic is a notable confounding factor in diagnosis and screening during this period. According to 2025 estimates from the American Lung Association, California has the third lowest rate of new lung cancer diagnoses in the nation, which may be partially explained by its comparatively low smoking rate, which is also the third lowest in the nation. However, just over 25% of lung cancer cases are caught at an early stage, placing California 43rd among the 50 states in terms of early detection screening. California also has a higher-than-average number of people who do not receive any treatment after being diagnosed with lung cancer, ranking 44th in the nation.
Affordable Care Act (ACA). Under the ACA, non-grandfathered group and individual health insurance plans and policies must cover certain preventive services without cost-sharing when delivered by in-network providers. The ACA prohibits copayments, coinsurance, and deductibles for preventive services that are determined based on recommendations by specified federally recognized groups and federal agencies, and must be covered without cost-sharing when provided in-network as soon as 12 months after a recommendation appears. For lung cancer screening, the USPSTF recommends an annual screening for lung cancer with low-dose CT scans in adults aged 50 to 80 years who have a 20 pack-year smoking history and currently smoke or have quit within the past 15 years. The screening should be discontinued once a person has not smoked for 15 years or develops a health problem that substantially limits life expectancy or the ability or willingness to have curative lung surgery. This recommendation is a grade B recommendation which means that coverage without a co-pay is required. This recommendation was most recently updated in March 2021. The guidelines are silent on any further testing beyond the annual scan, even if the results are inconclusive or require follow-up.
Internal Revenue Service (IRS) Preventive Services. Among the requirements to qualify as a health savings account, an individual must be covered under a high deductible health plan with no disqualifying health coverage. A high deductible health plan is a plan that satisfies certain requirements with respect to minimum deductibles and maximum out-of-pocket expenses. Generally, under federal law, a high deductible health plan linked to a health savings account may not provide benefits for any year until the minimum deductible for that year is satisfied. However, the law provides a safe harbor for the absence of a deductible for preventive care. Therefore, a high deductible health plan may provide preventive care benefits without a deductible. To be a preventive care benefit, the benefit must either be described as preventive care under the ACA or for purposes of the Social Security Act or determined to be preventive care in guidance issued by the Department of the Treasury and the IRS. Current IRS guidance does not include follow-up screening or diagnostic services for lung cancer.
California Health Benefits Review Program (CHBRP) analysis. AB 1996 (Thomson, Chapter 795, Statutes of 2002) requests the University of California to assess legislation proposing a mandated benefit or service and prepare a written analysis with relevant data on the medical, economic, and public health impacts of proposed health plan and health insurance benefit mandate legislation. CHBRP was created in response to AB 1996, and reviewed this bill. Key findings include:
- Screening guidelines. CHBRP found very strong evidence regarding the effectiveness of the initial lung cancer screening currently covered according to the ACA. With regards to the effectiveness of subsequent follow-up services after an abnormal or indeterminate finding, CHBRP did not review the evidence as diagnostic follow-up services have been well documented and thus the analysis assumes that follow-up services significantly improve health outcomes and reduce mortality.
- Coverage impacts and enrollees covered. CHBRP estimates that at baseline 40% of enrollees have coverage compliant with this bill, primarily Medi-Cal enrollees and a small number of CalPERS enrollees without cost-sharing for these services. Post-mandate, all 22.8 million Californians in state-regulated plans would have these services covered without cost-sharing.
- Medical effectiveness. CHBRP found strong evidence that delays in diagnoses and treatment are correlated with worse clinic stage during the diagnostic workup and increased recurrence of lung cancer. CHBRP found some evidence that treatment delays for lung cancer negatively impact mortality. While CHBRP found no direct evidence on the effectiveness of cost-sharing for follow-up services when patients have an abnormal finding during a lung cancer screening, evidence from other cancer research demonstrate how cost affects utilization of health services and outcomes.
- Utilization. CHBRP estimates that an additional 1,000 patients could access follow-up services for lung cancer, including imaging, biopsies, and surgical or other specialist consultations as a result of this bill. Post-mandate, a total of 51,000 Californians would utilize follow-up services without cost-sharing.
- Medi-Cal. CHBRP points out that Medi-Cal enrollees have no cost-sharing and all plans are currently compliant with this bill.
- Impact on expenditures. CHBRP estimates an increase of $27,641,000 in total annual premiums paid by employers and enrollees for covering benefits without cost-sharing. This translates to an additional $.06 to $.31 per member per month premium increase, depending on the type of coverage, with the highest increases being on individually purchased plans. For those needing the services, average annual out-of-pocket expenses would decrease in the commercial/CalPERS market, ranging from $90 (CalPERS) to $840 (individually purchased insurance). For those that do complete the recommended follow-up care, who would not have it without this bill, the average avoided treatment cost is approximately $149,304 per individual who receives an earlier-stage diagnosis. However, the number of individuals in this category is estimated to be very small and not sufficient to change the overall finding that premiums would increase overall.
- Public health. CHBRP projects a modest public health impact at the population level. However, the bill would likely yield health and quality-of-life improvements among a subset of enrollees who would receive diagnostic services and follow-up screenings without cost-sharing at a more frequent or earlier time interval. One study found that of those receiving an initial lung cancer screening, 7.4% had a follow-up procedure within one year. With regards to health disparities, the analysis states that Black, Native American and low-income populations face higher incidence and mortality rates, often driven by late-stage diagnosis and lower screening rates.
- Essential health benefits. If California requires state-regulated health insurance to offer benefits that exceed essential health benefits, the state could be required to defray the cost of additionally mandated benefits under the ACA. In this case, as the additional services are already covered as medically necessary basic health care services, the proposed mandate would not exceed the current definition of essential health benefits in California.
FISCAL EFFECT: Appropriation: No Fiscal Com.: Yes Local: Yes
According to the Senate Appropriations Committee this bill would have the following fiscal impacts:
- DMHC anticipates minor and absorbable costs for state administration.
- CDI estimates costs of $3,000 in 2026-27 and $16,000 in 2027-28 for state administration (Insurance Fund).
- Unknown General Fund costs, potentially hundreds of thousands, due to increased CalPERS plan premiums.
SUPPORT: (Verified 5/14/2026)
American Cancer Society Cancer Action Network (co-source)
American Lung Association (co-source)
Alliance for Patient Access
American Lung Cancer Screening Initiative
AstraZeneca
Biocom
Biomarker Collaborative
Breathe California
California Academy of Family Physicians
California Black Health Network
California Chronic Care Coalition
California Life Sciences
California Professional Firefighters
California Society for Respiratory Care
Cedars-Sinai Health Systems
Go2 for Lung Cancer
Health Access California
International Cancer Advocacy Network
OPPOSITION: (Verified 5/14/2026)
Association of California Life & Health Insurance Companies
California Association of Health Plans
California Small Business Association
ARGUMENTS IN SUPPORT: Supporters, including co-sponsors the American Cancer Society, the Cancer Action Network and the American Lung Association, write that many patients face substantial out-of-pocket costs for medically necessary follow-up diagnostics procedures after an abnormal screening result. These costs, which for some can be thousands of dollars, can discourage patients from completing essential follow-up testing, thereby delaying or preventing timely, potentially life-saving treatment. For individuals with limited financial resources, even modest co-pays can create substantial barriers. These burdens disproportionately impact low-income Californians, communities of color, and rural populations already experiencing higher lung cancer mortality rates.
ARGUMENTS IN OPPOSITION: The California Association of Health Plans and the Association of California Life and Health Insurance Companies write in opposition stating that this bill goes well beyond preventive services by eliminating cost-sharing for follow-up screening and diagnostic services. Moreover, eliminating cost-sharing for one category of diagnostic services while maintaining it for others sets a troubling precedent and raises concerns about consistency and equity across the health care system. These added costs ultimately increase premiums and shift financial burdens onto other purchasers and enrollees, at a time when health care affordability remains a pressing concern for Californians. The California Small Business Association writes in opposition to a number of health care mandate bills, including this one, pointing out that these bills increase the costs to employer-sponsored health coverage.
Prepared by: Jen Flory / HEALTH / (916) 651-4111
5/14/26 16:56:03
**** END ****
SENATE COMMITTEE ON
Senator Sabrina Cervantes, Chair
2025 - 2026 Regular Session
SB 1309 (Rubio) - Health care coverage: lung cancer
Version: | Policy Vote: |
Urgency: | Mandate: |
Hearing Date: | Consultant: |
Bill Summary:
SB 1309 would require health plans and insurers to provide coverage without cost-sharing for follow-up screening or diagnostic services for lung cancer.
Fiscal Impact:
- The Department of Managed Health Care (DMHC) anticipates minor and absorbable costs for state administration.
- The California Department of Insurance (CDI) estimates costs of $3,000 in 2026-27 and $16,000 in 2027-28 for state administration (Insurance Fund).
- Unknown General Fund costs, potentially hundreds of thousands, due to increased CalPERS plan premiums.
Background:
Current state law requires health plans and insurers to provide coverage for and not impose any cost-sharing requirements for any evidence-based items or services that had in effect a rating of “A” or “B” in the recommendations of the United States Preventive Services Task Force (USPSTF) on January 1, 2025 or, as later modified by the California Department of Public Health (CDPH).
For lung cancer screening, the USPSTF recommends an annual screening for lung cancer with low-dose CT scans in adults aged 50 to 80 years who have a 20 pack-year smoking history and currently smoke or have quit within the past 15 years. The screening should be discontinued once a person has not smoked for 15 years or develops a health problem that substantially limits life expectancy or the ability or willingness to have curative lung surgery. This recommendation is a grade “B” recommendation which means that this annual screening is covered without enrollee cost-sharing. The USPSTF guidelines are silent on any further testing beyond the annual screening, even if the results are inconclusive or require follow-up. While the initial screening with a low-dose CT is covered without enrollee cost-sharing, follow-up services needed to make a diagnosis (including CT scans, tissue sampling, specialist consultations) may require enrollee cost-sharing.
Proposed Law:
Specific provisions of the bill would:
- Require health plans and insurers to provide coverage for follow-up screening or diagnostic services for lung cancer recommended by a health care provider acting within the scope of their practice; and prohibit this coverage from being subject to copayment, coinsurance, deductible, or any other form of cost-sharing.
- Define “follow-up screening or diagnostic services for lung cancer” to mean a service provided after an initial abnormal or indeterminate test result, including, but not limited to, a diagnostic computed tomography scan, positron emission tomography/computed tomography scan, tissue sampling, biopsy, bronchoscopy, pathology, and surgical consultation.
Related Legislation:
SB 1124 (Archuleta) would require a retailer engaged in the retail sale of cigarettes or tobacco products to prominently display signage regarding lung cancer screening. The bill is scheduled to be heard May 4, 2026 in this committee.
AB 1570 (Wilson) would require health plans and insurers to provide coverage without cost-sharing for screening mammography, medically necessary diagnostic or supplemental breast examinations, diagnostic mammography, and medically necessary diagnostic breast imaging. The bill is currently in the Assembly Appropriations Committee.
Staff Comments:
According to the California Health Benefits Review Program (CHBRP) analysis of SB 1309 (introduced version), CHBRP estimates an increase of $27,641,000 in total annual premiums paid by employers and enrollees for covering benefits without cost-sharing. This includes an increase of $544,000 in CalPERS employer premiums.
-- END --
SENATE COMMITTEE ON HEALTH
Senator Dr. Akilah Weber Pierson, Chair
BILL NO: SB 1309
AUTHOR: | Rubio | ||
VERSION: | April 14, 2026 | ||
HEARING DATE: | April 22, 2026 | ||
CONSULTANT: | Jen Flory | ||
SUBJECT: Health care coverage: lung cancer
SUMMARY:
Requires a health plan contract or health insurance policy to provide, without cost-sharing, coverage for follow-up screening or diagnostic services for lung cancer that is recommended by a health care provider acting within the scope of their practice.
Existing law:
- Establishes the Department of Managed Health Care (DMHC) to regulate health plans under the Knox-Keene Health Care Service Plan Act of 1975 (Knox-Keene Act); California Department of Insurance (CDI) to regulate health and other insurance; and, the Department of Health Care Services (DHCS) to administer the Medi-Cal program. [HSC §1340, et seq., INS §106, et seq., and WIC §14000, et seq.]
- Requires a health plan contract and health insurance policy, except for a specialized health plan contract and policy, to be deemed to provide coverage for all generally medically accepted cancer screening tests, subject to all terms and conditions that would otherwise apply. [HSC §1367.665 and INS §10123.20]
- Requires a group or individual nongrandfathered health plan contract or health insurance policy, at a minimum, to provide coverage for and not impose any cost-sharing requirements for any of the following:
- Evidence-based items or services that had in effect a rating of “A” or “B” in the recommendations of the United States Preventive Services Task Force (USPSTF) on January 1, 2025 or, as later modified by the California Department of Public Health (CDPH);
- Immunizations that had in effect a recommendation from the Advisory Committee on Immunization Practices of the federal Centers for Disease Control and Prevention (CDC) on January 1, 2025 or as later modified by CDPH;
- With respect to infants, children, and adolescents, evidence-informed preventive care and screenings provided in the comprehensive guidelines supported by the United States Health Resources and Services Administration (HRSA) as of January 1, 2025 or as later modified by CDPH;
- With respect to women, those additional preventive care and screenings as provided for in comprehensive guidelines supported by the HRSA as of January 1, 2025 or as later modified by CDPH; and,
- Indicates the recommendations of the USPSTF regarding breast cancer screening, mammography, and prevention as of January 1, 2025, or as later modified by CDPH, is considered the most current other than those issued in or around November 2009. [HSC§ 1367.002 and INS §10112.2]
- Establishes health savings accounts under federal law, to be used exclusively for the purpose of paying the qualified medical expenses of the account beneficiary, but only if the written governing instrument creating the trust meets specified requirements. Establishes high deductible health plans, which are plans with deductibles not less than $1,000 for an individual and $5,000 for a family, as specified. [26 USC §223]
- Allows an annual tax deduction in an amount equal to the aggregate amount paid in cash by or on behalf of an individual, to a health savings account. [26 USC §223]
- Prohibits a plan from failing to be treated as a high deductible health plan by reason of failing to have a deductible for preventive care, as specified. [26 USC §223]
This bill:
- Requires a health plan contract or health insurance policy issued, amended, or renewed on or after January 1, 2027 to provide coverage for follow-up screening or diagnostic services for lung cancer recommended by a health care provider acting within the scope of their practice.
- Specifies that this coverage is not subject to copayment, coinsurance, deductible or any other form of cost-sharing.
- Defines “follow-up screening or diagnostic services for lung cancer” as a service provided after an initial abnormal or indeterminate test result, including, but not limited to a diagnostic computed tomography scan, positron emission tomography/computed tomography scan, tissue sampling, biopsy, bronchoscopy, pathology, and surgical consultation.
FISCAL EFFECT:
This bill has not been analyzed by a fiscal committee.
COMMENTS:
- Author’s statement. According to the author, lung cancer is the leading cause of cancer-related death in California, yet it is one of the most survivable cancers when caught early. The problem is that too many Californians are skipping life-saving screenings. Not because they do not want to take care of their health, but because they simply cannot afford to be screened. This bill, the Stop Lung Cancer Early Act, directly addresses this barrier by eliminating cost-sharing for lung cancer screenings. There is no reason to delay the care that could save your life. When a screening returns an abnormal or intermediate result, patients need timely follow-up care to determine next steps, yet this is often where the financial burden becomes overwhelming. This bill eliminates cost-sharing for that follow-up care, ensuring patients are not left without answers at the most critical moment in their health journey. The data is clear: when lung cancer is caught at an early stage, survival rates increase dramatically. By removing financial obstacles at every step of the screening and diagnostic process, this bill will encourage more Californians to get screened, more cancers to be caught early, and ultimately, more lives to be saved. No Californian should have to choose between their financial stability and a fighting chance against cancer.
- Lung Cancer in California. Lung cancer is the third most common cancer and the leading cause of cancer deaths in California, according to data from a 2019 UC Davis Comprehensive Cancer Center report. Smoking and secondhand smoke are the leading risk factors, followed by radon exposure and air pollution. The California Tobacco Control Program’s estimate of lung and bronchus cancer incidence in California decreased from 41.2 to 33.8 per 100,000 adults between 2016 and 2021, although the COVID-19 pandemic is a notable confounding factor in diagnosis and screening during this period. According to 2025 estimates from the American Lung Association, California has the third lowest rate of new lung cancer diagnoses in the nation, which may be partially explained by its comparatively low smoking rate, which is also the third lowest in the nation. However, just over 25% of lung cancer cases are caught at an early stage, placing California 43rd among the 50 states in terms of early detection screening. California also has a higher-than-average number of people who do not receive any treatment after being diagnosed with lung cancer, ranking 44th in the nation.
- Affordable Care Act (ACA). Under the ACA, non-grandfathered group and individual health insurance plans and policies must cover certain preventive services without cost-sharing when delivered by in-network providers. The ACA prohibits copayments, coinsurance, and deductibles for preventive services that are determined based on recommendations by specified federally recognized groups and federal agencies, and must be covered without cost-sharing when provided in-network as soon as 12 months after a recommendation appears. For lung cancer screening, the USPSTF recommends an annual screening for lung cancer with low-dose CT scans in adults aged 50 to 80 years who have a 20 pack-year smoking history and currently smoke or have quit within the past 15 years. The screening should be discontinued once a person has not smoked for 15 years or develops a health problem that substantially limits life expectancy or the ability or willingness to have curative lung surgery. This recommendation is a grade B recommendation which means that coverage without a co-pay is required. This recommendation was most recently updated in March 2021. The guidelines are silent on any further testing beyond the annual scan, even if the results are inconclusive or require follow-up.
- Internal Revenue Service (IRS) Preventive Services. Among the requirements to qualify as a health savings account, an individual must be covered under a high deductible health plan with no disqualifying health coverage. A high deductible health plan is a plan that satisfies certain requirements with respect to minimum deductibles and maximum out-of-pocket expenses. Generally, under federal law, a high deductible health plan linked to a health savings account may not provide benefits for any year until the minimum deductible for that year is satisfied. However, the law provides a safe harbor for the absence of a deductible for preventive care. Therefore, a high deductible health plan may provide preventive care benefits without a deductible. To be a preventive care benefit, the benefit must either be described as preventive care under the ACA or for purposes of the Social Security Act or determined to be preventive care in guidance issued by the Department of the Treasury and the IRS. Current IRS guidance does not include follow-up screening or diagnostic services for lung cancer.
- California Health Benefits Review Program (CHBRP) analysis. AB 1996 (Thomson, Chapter 795, Statutes of 2002) requests the University of California to assess legislation proposing a mandated benefit or service and prepare a written analysis with relevant data on the medical, economic, and public health impacts of proposed health plan and health insurance benefit mandate legislation. CHBRP was created in response to AB 1996, and reviewed this bill. Key findings include:
- Screening guidelines. CHBRP found very strong evidence regarding the effectiveness of the initial lung cancer screening currently covered according to the ACA. With regards to the effectiveness of subsequent follow-up services after an abnormal or indeterminate finding, CHBRP did not review the evidence as diagnostic follow-up services have been well documented and thus the analysis assumes that follow-up services significantly improve health outcomes and reduce mortality.
- Coverage impacts and enrollees covered. CHBRP estimates that at baseline 40% of enrollees have coverage compliant with this bill, primarily Medi-Cal enrollees and a small number of CalPERS enrollees without cost-sharing for these services. Post-mandate, all 22.8 million Californians in state-regulated plans would have these services covered without cost-sharing.
- Medical effectiveness. CHBRP found strong evidence that delays in diagnoses and treatment are correlated with worse clinic stage during the diagnostic workup and increased recurrence of lung cancer. CHBRP found some evidence that treatment delays for lung cancer negatively impact mortality. While CHBRP found no direct evidence on the effectiveness of cost-sharing for follow-up services when patients have an abnormal finding during a lung cancer screening, evidence from other cancer research demonstrate how cost affects utilization of health services and outcomes.
- Utilization. CHBRP estimates that an additional 1,000 patients could access follow-up services for lung cancer, including imaging, biopsies, and surgical or other specialist consultations as a result of this bill. Post-mandate, a total of 51,000 Californians would utilize follow-up services without cost-sharing.
- Medi-Cal. CHBRP points out that Medi-Cal enrollees have no cost-sharing and all plans are currently compliant with this bill.
- Impact on expenditures. CHBRP estimates an increase of $27,641,000 in total annual premiums paid by employers and enrollees for covering benefits without cost-sharing. This translates to an additional $.06 to $.31 per member per month premium increase, depending on the type of coverage, with the highest increases being on individually purchased plans. For those needing the services, average annual out-of-pocket expenses would decrease in the commercial/CalPERS market, ranging from $90 (CalPERS) to $840 (individually purchased insurance). For those that do complete the recommended follow-up care, who would not have it without this bill, the average avoided treatment cost is approximately $149,304 per individual who receives an earlier-stage diagnosis. However, the number of individuals in this category is estimated to be very small and not sufficient to change the overall finding that premiums would increase overall.
- Public health. CHBRP projects a modest public health impact at the population level. However, the bill would likely yield health and quality-of-life improvements among a subset of enrollees who would receive diagnostic services and follow-up screenings without cost-sharing at a more frequent or earlier time interval. One study found that of those receiving an initial lung cancer screening, 7.4% had a follow-up procedure within one year. With regards to health disparities, the analysis states that Black, Native American and low-income populations face higher incidence and mortality rates, often driven by late-stage diagnosis and lower screening rates.
- Essential health benefits. If California requires state-regulated health insurance to offer benefits that exceed essential health benefits, the state could be required to defray the cost of additionally mandated benefits under the ACA. In this case, as the additional services are already covered as medically necessary basic health care services, the proposed mandate would not exceed the current definition of essential health benefits in California.
- Related legislation. SB 950 (Weber Pierson) requires health plans and insurers to cover all medically necessary treatments or medications, as determined by a health care provider, that are approved by the federal Food and Drug Administration for the treatment of Alzheimer’s disease or other related dementia. SB 950 passed this committee by a vote of 9-0 when it was heard in this committee on April 15, 2026.
SB 1124 (Archuleta) requires CDPH to develop signage for lung cancer screening by July 1, 2027, and mandates that retailers prominently display this signage in retail locations beginning January 1, 2028. Creates a $1,000 penalty for failure to display the signage, enforceable by the California Department of Tax and Fee Administration. SB 1124 is set for hearing in the Senate Revenue & Taxation Committee on April 22, 2026.
AB 1570 (Wilson) requires health plans and insurers to cover an annual cervical cancer screening home test kit without cost-sharing. AB 1570 is set for hearing in the Assembly Appropriations Committee on April 22, 2026.
AB 1906 (Aguiar-Curry) requires health plans, health insurance, and Medi-Cal to cover screening mammography and medically necessary diagnostic breast imaging, including imaging following an abnormal mammography for an enrollee or insured with a breast cancer risk factor without cost-sharing. AB 1906 is set for hearing in the Assembly Health Committee on April 21, 2026.
- Support. Supporters, including co-sponsors the American Cancer Society, the Cancer Action Network and the American Lung Association, write that many patients face substantial out-of-pocket costs for medically necessary follow-up diagnostics procedures after an abnormal screening result. These costs, which for some can be thousands of dollars, can discourage patients from completing essential follow-up testing, thereby delaying or preventing timely, potentially life-saving treatment. For individuals with limited financial resources, even modest co-pays can create substantial barriers. These burdens disproportionately impact low-income Californians, communities of color, and rural populations already experiencing higher lung cancer mortality rates.
- Opposition. The California Association of Health Plans and the Association of California Life and Health Insurance Companies write in opposition stating that this bill goes well beyond preventive services by eliminating cost-sharing for follow-up screening and diagnostic services. Moreover, eliminating cost-sharing for one category of diagnostic services while maintaining it for others sets a troubling precedent and raises concerns about consistency and equity across the health care system. These added costs ultimately increase premiums and shift financial burdens onto other purchasers and enrollees, at a time when health care affordability remains a pressing concern for Californians. The California Small Business Association writes in opposition to a number of health care mandate bills, including this one, pointing out that these bills increase the costs to employer-sponsored health coverage.
- Policy comment. While the argument that the high cost of follow-up care deters people from getting the additional diagnostic tests they need after an abnormal or inconclusive initial lung cancer screening test is compelling, the same argument can be made for the cost of lung cancer treatment itself, or indeed, any health care service. Earlier diagnosis and care is always better and cost always deters access to services. California’s high rate of persons who receive no treatment after being diagnosed with lung cancer is testament to this fact.
- Amendments. As currently drafted, the requirements of this bill could be interpreted to apply to specialty health plans, such as dental plans, that would not normally cover these services. This is not an issue for health insurance policies given how they are already defined in the Insurance Code. As such, the following technical amendment will be made to the Health and Safety section that regulates health plans:
Section 1 1367.58. (a) A health care service plan contract, excluding a specialized health care service plan contract, issued, amended, or renewed on or after January 1, 2027, shall provide coverage for follow-up screening or diagnostic services for lung cancer recommended by a health care provider acting within the scope of their practice.
As noted above, health savings account eligible high deductible health plans must meet federal requirements and can only exclude services from cost-sharing as authorized by the IRS. Thus, the following amendment to the section on health plans requires these plans to exclude the additional services from cost-sharing only when authorized federally:
(d) If a health care service plan contract is a high deductible health plan, as defined in Section 223(c)(2) of Title 26 of the United States Code, the contract shall not impose a deductible, coinsurance, or any other cost-sharing on the services described in this section unless doing so would conflict with the current federal requirements for high deductible health plans, including those requirements defining exempt preventive care.
SUPPORT AND OPPOSITION:
Support: American Cancer Society Cancer Action Network (co-sponsor)
American Lung Association (co-sponsor)
Alliance for Patient Access
American Lung Cancer Screening Initiative
AstraZeneca
Biocom
Biomarker Collaborative
Breathe California
California Academy of Family Physicians
California Black Health Network
California Chronic Care Coalition
California Life Sciences
California Society for Respiratory Care
Cedars-Sinai Health Systems
Go2 for Lung Cancer
Health Access California
International Cancer Advocacy Network
Oppose: Association of California Life & Health Insurance Companies
California Association of Health Plans
California Small Business Association
-- END -
Discussed in Hearing
Assembly Standing Committee on Health
Senate Floor
Senate Standing Committee on Health
Bill Author
Bill Co-Author(s):